BRIEF published on 11/20/2026 at 07:05, 2 days 1 hour ago BioVersys Unveils Promising Phase 2a Results for Tuberculosis Treatment Phase 2a BioVersys Tuberculosis AlpE ENABLE Study
PRESS RELEASE published on 11/20/2026 at 07:00, 2 days 1 hour ago BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE
BRIEF published on 11/11/2026 at 07:05, 11 days 1 hour ago BioVersys to Present Alpibectir Data at Global Lung Health Conference Conference GSK BioVersys Tuberculosis Alpibectir
PRESS RELEASE published on 11/11/2026 at 07:00, 11 days 1 hour ago BioVersys and partners to present AlpE data at The Union World Conference on Lung Health
BRIEF published on 10/29/2026 at 07:05, 24 days 1 hour ago BioVersys Initiates Phase 2b RIV-CARE Trial of BV100 Clinical Trials Antibiotic Resistance BioVersys AG BV100 RIV-CARE Trial
PRESS RELEASE published on 10/29/2026 at 07:00, 24 days 1 hour ago BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100
BRIEF published on 10/22/2026 at 07:05, 1 month ago BioVersys Unveils BV100 Phase 2 Data at IDWeek 2026 Antimicrobial Resistance Phase 2 Trial BV100 BioVersys IDWeek 2026
PRESS RELEASE published on 10/22/2026 at 07:00, 1 month ago BioVersys’ BV100 Phase 2 exploratory data selected for rapid fire and poster presentations at IDWeek 2026 BioVersys presents Phase 2 exploratory data on BV100 for ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii at IDWeek 2026 Phase 2 BV100 Antibacterial Products BioVersys IDWeek 2026
BRIEF published on 10/20/2026 at 07:05, 1 month 2 days ago BioVersys Publishes BV100 Lung Penetration Data BV100 BioVersys Lung Penetration Drug Interactions CRAB Pneumonia
PRESS RELEASE published on 10/20/2026 at 07:00, 1 month 2 days ago BioVersys announces publication of BV100 lung penetration and drug interaction data in two leading peer-reviewed antimicrobial journals BioVersys AG announces publication of BV100 lung penetration and drug interaction data in two leading peer-reviewed antimicrobial journals BioVersys AG BV100 Lung Penetration Drug Interaction Antimicrobial Therapy
Published on 11/20/2026 at 15:00, 1 day 17 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 17 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 18 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 18 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 18 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 8 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 10 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 12 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 13 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 13 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 14 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 13 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 23 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing